An AI-Health infrastructure for the Nordic region: technical foundations, data assets, and a roadmap for deployment

In this Comment, we outline the Nordic AI-Health Initiative platform, built on unique large-scale longitudinal and multimodal health data sets from across the region. The platform is designed to enable secure, regulation-compliant access and to deliver generalizable models for responsible AI-driven discovery in medicine. This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article - Purchase on SpringerLink - Instant access to the full article PDF. USD 39.95 Prices may be subject to local taxes which are calculated during checkout References Han, R. et al. Lancet Digit. Health 6, e367–e373 (2024). Moor, M. et al. Nature 616, 259–265 (2023). Njolstad, P. R. et al. Nat. Genet. 51, 924–930 (2019). Laugesen, K. et al. Clin. Epidemiol. 13, 533–554 (2021). Kurki, M. I. et al. Nature 613, 508–518 (2023). Milani, L. et al. Nat. Commun. 16, 3270 (2025). Arnar, D. O. et al. Eur. J. Intern. Med. 41, 3–9 (2017). Shmatko, A. et al. Nature 647, 248–256 (2025). Acosta, J. N. et al. Nat. Med. 28, 1773–1784 (2022). Bronstein, M. M. et al. Preprint at https://doi.org/10.48550/arXiv.2104.13478 (2021). Rieke, N. et al. npj Digit. Med. 3, 119 (2020). Lekadir, K. et al. BMJ 388, e081554 (2025). Obermeyer, Z. et al. Science 366, 447–453 (2019). Reas, E. T. et al. Alzheimers Dement. 19, 5151–5158 (2023). Kallioniemi, O. et al. Sitra Rep. www.sitra.fi/julkaisut/terveystiedon-tulevaisuus-tekoalyn-aikakaudella/ (2026). Acknowledgements The authors thank S. Sævarsdóttir for constructive discussions. Generative AI tools were used to improve readability, grammar, and language, and all authors reviewed and approved the final version of the manuscript. O.A.A. received funding from Nordforsk, Novo Nordisk Foundation, Research Council of Norway, KG Jebsen Stiftelsen, European Union’s Horizon 2020 and Horizon Europe research and innovation programs. H.H. received funding from the Lundbeck Foundation. T.L. received funding from Knut and Alice Wallenberg Foundation, European Research Council, Swedish Research Council, and National Institutes of Health. P.R.N. was supported by funds from the European Research Council, Novo Nordisk Foundation, Danish Diabetes & Endocrinology Academy, Trond Mohn Foundation, KG Jebsen Stiftelsen, Meltzer Foundation. M.V. was supported by the Research Council of Norway, European Research Council, University of Bergen. S.R., J.V. and L.M.: this work has received funding from the European Union’s Horizon Europe research and innovation program under grant agreement no. 101060011. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. T.W. received funding from the European Partnership for Personalised Medicine, Novo Nordisk Foundation, US National Institute of Mental Health. S.B. received funding from Novo Nordisk Foundation. O.K. received funding from the Research Council of Finland, Finnish Medical Foundation, Sigrid Juselius Foundation and the Jane and Aatos Erkko Foundation, KAW, Vetenskapsrådet, and CancerFonden (Sweden). Author information Authors and Affiliations Corresponding author Ethics declarations Competing interests O.A.A. is a consultant to Precision-Health.ai and Ledidi, and has received speaker’s honoraria from Eli Lilly and Company, Bristol Myers Squibb, H. Lundbeck A/S, Otsuka Pharmaceutical Co, Sunovion Pharmaceuticals Inc., and Janssen Pharmaceuticals. D.A. has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, Evonik, Roche Diagnostics, and GE Health, Sanofi, and served as a paid consultant for H. Lundbeck, Eisai, Heptares, Eli Lilly, Enterin, Acadia, EIP Pharma, Biogen, and Takeda, Eli Lilly, Eisai, BioArctic. T.L. is an advisor with equity in Variant Bio. A.S. is an employee at AbbVie, a biopharmaceutical company. AbbVie has not provided funding for the development of this paper and has no role in the decision to publish. L.M. has received travel reimbursement from Pacific Biosciences for attending meetings to present research results. A.M.D. is a founding director of, and holds equity in, CorTechs Labs Inc. (DBA Cortechs.ai), Precision Pro Inc., and Precision Health and Wellness Inc. A.M.D. is the president and a board of trustees member of the J. Craig Venter Institute. H.S. and D.G. are employees at Amgen deCODE genetics. S.B. has received speakers’ honoraria from Sanofi and Roche. O.K. is founder and shareholder in Sartar Therapeutics and received honoraria from KAW, Novo Nordisk Foundation and Sitra. Rights and permissions About this article Cite this article Andreassen, O.A., Heimer, H., Aarsland, D. et al. An AI-Health infrastructure for the Nordic region: technical foundations, data assets, and a roadmap for deployment. Nat Med (2026). https://doi.org/10.1038/s41591-026-04575-4 Published: Version of record: DOI: https://doi.org/10.1038/s41591-026-04575-4